Barber MD, Ross JA, Voss AC, Tisdale MJ & Fearon KC (1999 a) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. British Journal of Cancer 81(1), 80–86.
Barber MD, Ross JA, Preston T, Shenkin A & Fearon KC (1999 b) Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. Journal of Nutrition 129(6), 1120–1125.
Barber MD, McMillan DC, Preston T, Ross JA & Fearon KC (2000) Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by fish-oil-enriched nutritional supplement. Clinical Science 98, 389–399.
Barber MD, Fearon KC, Tisdale MJ, McMillan DC & Ross JA (2001 a) Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutrition & Cancer 40(2), 118–124.
Barber MD & Fearon KC (2001 b) Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 36(4), 347–351.
Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G & Baracos V (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. Journal of Clinical Oncology 21(1), 129–134.
Burns CP, Halabi S, Clamon GH, Hars V, et al. (1999) Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukaemia group B. Clinical Cancer Research 5, 3942–3947.
Burns P, Halabi S, Clamon G, Kaplan E, et al. (2004) Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. A Cancer and Leukemia Group B study. Cancer 101, 370–378.
Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, Goedhart A, Lundholm K, Nitenberg G & Stratton RJ (2006) Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. International Journal of Oncology 28(1), 5–23.
Fearon KC, Von Meyenfeldt MF, Moses AG, et al. (2003) Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut 52(10), 1479–1486.
Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoumbos NC & Kalfarentzos F (1998) Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 82(2), 395–402.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Renolds JM, Gavaghan DJ & McQuay HJ (1996) Assessing the quality of reports on randomized clinical trials: Is blinding necessary? Controlled Clin Trials 17, 1–12.
Jatoi A, Rowland K, Loprinzi CL, Sloan JA, et al. (2004) An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22, 2469–2476.
Jovell JA & Navarro Rubio MD (1995) Evaluación de la evidencia científica. Med Clin 105, 26–29.
Karmali R (1996) Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Nutrition 12, S2–S4.
Kelley DS (2001) Modulating of human immune and inflammatory responses by dietary fatty acids. Nutrition 17, 669–673.
Kenler AS, Swails WS, Driscoll DF, et al. (1996) Early enteral feeding in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula. Annals of Surgery 223(3), 316–333.
Meydani S (1996) Effects of (n-3) polyunsaturated fatty acids on cytokine production and their biological function. Nutrition 12, S8–S14.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D & Stroup DF (1999) Improving the quality of randomised controlled trials meta-analyses reports: the QUOROM statement. Quality of reporting Meta-analyses. Lancet 354(9193), 1896–1900.
Moses AWG, Slater C, Preston T, Barber MD & Fearon KC (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. British Journal of Cancer 90, 996–1002.
Resolution ResAP (2003).
Roynette CE, Calder P, Dupertuis YM & Pichard C (2004) N-3 polyunsaturated fatty acids and colon cancer prevention. Clin Nutr 23, 139–151.
Swails WS, Kenler AS, Driscoll DF, et al. (1997) Effect of a fish oil structured lipid-based diet on prostaglandin release from mononuclear cells in cancer patients after surgery. Journal of Parenteral & Enteral Nutrition 21(5), 266–274.
Vancassel S, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres C & Chalon S (2001) Plasma fatty acid levels in autistic children. Prostaglandins Leukotrienes and Essential Fatty Acids 65(1), 1–7.
Voss AC & Gallagher-Allred C (1996) The importance of outcomes research in documenting the benefit of nutrition intervention. Nutrition 12, 59–60.
Wigmore SJ, Ross JA, Falconer JS, et al. (1996) The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12(Suppl. 1), S27–S30.
Wigmore SJ, Barber MD, Ross JA, Tisdale MJ & Fearon KC (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutrition & Cancer 36(2), 177–184.
Xia S-H, Wang J & Kang JX (2005) Decreased n-6/n-3 fatty acid ratio reduces the invasive potential of human lung cancer cells by down regulation of cell adhesion/invasion-related genes. Carcinogenesis 26, 779–784.
Zuijdgeest-Van Leeuwen SD, Dagnelie PC, Wattimena JL, et al. (2000) Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation. Clinical Nutrition 19(6), 417–423.